anti- AGER antibody
Pida mas información
935106861
info@markelab.com
Precio
Precio a consultar
Antibody anti-AGER
proveedor
FineTestreference
FNab00209Tested Applications
ELISA, WB, IHCreactivity
human,mouse,ratstatus
RUOclonality
polyclonalDescripción
Mediates interactions of advanced glycosylation end products(AGE). These are nonenzymatically glycosylated proteins which accumulate in vascular tissue in aging and at an accelerated rate in diabetes. Acts as a mediator of both acute and chronic vascular inflammation in conditions such as atherosclerosis and in particular as a complication of diabetes. AGE/RAGE signaling plays an important role in regulating the production/expression of TNF-alpha, oxidative stress, and endothelial dysfunction in type 2 diabetes. Interaction with S100A12 on endothelium, mononuclear phagocytes, and lymphocytes triggers cellular activation, with generation of key proinflammatory mediators. Interaction with S100B after myocardial infarction may play a role in myocyte apoptosis by activating ERK1/2 and p53/TP53 signaling(By similarity). Receptor for amyloid beta peptide. Contributes to the translocation of amyloid-beta peptide(ABPP) across the cell membrane from the extracellular to the intracellular space in cortical neurons. ABPP-initiated RAGE signaling, especially stimulation of p38 mitogen-activated protein kinase(MAPK), has the capacity to drive a transport system delivering ABPP as a complex with RAGE to the intraneuronal space. Can also bind oligonucleotides.
Background
AGER, also known as RAGE (Receptor for Advanced Glycation End Products), is a transmembrane receptor belonging to the immunoglobulin superfamily that binds to AGEs and other ligands such as S100 proteins, HMGB1, and amyloid-β. AGER is widely expressed, particularly in the endothelium, lungs, brain, and immune cells, and plays a critical role in inflammatory and oxidative stress signaling. Binding of AGEs to AGER activates downstream pathways, including NF-κB, MAPK, and JAK/STAT, leading to the production of pro-inflammatory cytokines and reactive oxygen species. Overexpression or chronic activation of AGER is associated with diseases such as diabetes complications, atherosclerosis, Alzheimer’s disease, and cancer, where it exacerbates inflammation and tissue damage. AGER is a promising therapeutic target for reducing AGE-mediated pathologies and modulating immune and metabolic dysfunction.
Características del producto
category
Primary Antibodies
clonality
polyclonal
reactivity
human,mouse,rat
immunogen target
advanced glycosylation end product-specific receptor
host
Rabbit
isotype
IgG
conjugation
Unconjugated
form
liquid
tested applications
ELISA, WB, IHC
observerd MW
43 kDa
purity
≥95% as determined by SDS-PAGE
purification
Immunogen affinity purified
recommended dilution
WB: 1:200-1:2000; IHC: 1:20-1:200
size 1
100µg
storage
PBS with 0.02% sodium azide and 50% glycerol pH 7.3,-20℃ for 12 months(Avoid repeated freeze / thaw cycles.)
or code
AGER
alias
RAGE,SCARJ1,sRAGE
uniprot id
note
This product is for research use only.
Quizá le pueda interesar
Mouse AGER(Advanced Glycosylation End Product Specific Receptor) ELISA Kit
proveedor
FineTestreference
EM0526reactivity
mousestatus
RUOPrecio a consultar
Ver másanti- AGER antibody
proveedor
FineTestreference
FNab00209Tested Applications
ELISA, WB, IHCreactivity
human,mouse,ratstatus
RUOclonality
polyclonalMediates interactions of advanced glycosylation end products(AGE). These are nonenzymatically glycosylated proteins whic...
Precio a consultar
Ver másanti- AGER antibody
proveedor
FineTestreference
FNab09951Tested Applications
ELISA, WBreactivity
human,ratstatus
RUOclonality
monoclonalMediates interactions of advanced glycosylation end products(AGE). These are nonenzymatically glycosylated proteins whic...
Precio a consultar
Ver más